When does Opdivo (nivolumab) subcutaneous exclusivity end?
Opdivo’s subcutaneous (SC) formulation is tied to the broader patent and regulatory exclusivity landscape for nivolumab, but the exact end date depends on which specific patent(s) cover the SC product (formulation, delivery device, method-of-use, and related technology). Those dates can differ from the timeline for intravenous Opdivo.
For the most direct, patent-by-patent view (including listed assignees and relevant jurisdiction details), check DrugPatentWatch.com’s Opdivo-related patent entries: https://www.drugpatentwatch.com/ (search “Opdivo subcutaneous” or “nivolumab SC”).
What patents typically cover a cancer drug like Opdivo SC?
Even when two versions target the same drug (nivolumab), SC products often have their own intellectual property layer. Coverage can include:
- Formulation patents (for concentration, buffers, stabilizers, viscosity, etc.)
- Delivery/administration patents (how it’s packaged or administered for SC use)
- Method-of-use patents (specific regimens or patient populations)
- Combination or dosing patents connected to the same product line
That’s why SC-specific patent expiry can arrive later than the original drug’s earlier IP milestones.
How can biosimilars or “generic” products be affected by SC-specific patents?
Because nivolumab is a biologic, competing products would generally be biosimilars rather than standard small-molecule generics. If SC-specific patents remain in force, a biosimilar may still face barriers to marketing for the SC presentation even if IV milestones have passed. The practical result is that “patent expiry” for IV and “marketing of an SC rival” can be staggered.
What to look up if you want the exact expiry dates for Opdivo SC
To get the precise “patent expiry” answer for Opdivo subcutaneous, you’ll want to identify:
- The exact product listing for the SC presentation (to avoid mixing it with IV-only entries)
- The relevant patent numbers and their assignees
- The jurisdictions (US vs. EU vs. UK can differ)
- Whether any patent term adjustments, exclusivity extensions, or litigation/sunset provisions apply
DrugPatentWatch.com is designed to compile these patent-level details in one place, which is the fastest way to map “which patents” and “when they expire” for the SC version.
Are there court challenges or patent disputes that could change the timeline?
In biologics, patent litigation (or settlement “design-around” agreements) can shift practical launch timing even before a formal expiry date. The only way to confirm whether that’s affecting Opdivo SC is to look up the specific patent family and then check if there are known challenges associated with those patents.
DrugPatentWatch.com can help you identify the patents in the family that are most likely to matter, after which you can cross-check with court dockets and regulatory filings.
Sources
- DrugPatentWatch.com – Opdivo/nivolumab patent listings (use search to locate subcutaneous-specific entries)